Endothelial cell (EC) dysfunction plays a role in the pathobiology of occlusive vasculopathy in 32 pulmonary arterial hypertension (PAH). Purinergic signalling pathways, which consists of 33 extracellular nucleotide and nucleoside mediated cell signalling through specific receptors, are 34 known to be important regulators of vascular tone and remodelling. Therefore, we 35 hypothesized that abnormalities in the vascular purinergic microenvironment are associated 36 with PAH. Enzymatic clearance is crucial to terminate unnecessary cell activation; one of the 37 most abundantly expressed enzyme on EC surface is E-NTPDase1/CD39, which hydrolyses 38 ATP and ADP to AMP. We used histological samples from patients and healthy donors, 39 radioisotope labelled substrates to measure ecto-enzyme activity, and a variety of in vitro 40 approaches to study the role of CD39 in PAH. Immunohistochemistry on human idiopathic 41 PAH patients´ lungs demonstrated that CD39 was significantly down-regulated in the 42 endothelium of diseased small arteries. Similarly, CD39 expression and activity were 43 decreased in cultured pulmonary ECs from IPAH patients. Suppression of CD39 in vitro 44 resulted in EC phenotypic switch that gave rise to apoptosis resistant pulmonary arterial 45 endothelial cells, and promoted a microenvironment that induced vascular smooth muscle cell 46 migration. We also identified that the ATP receptor P2Y11 is essential for ATP-mediated EC 47 survival. Furthermore, we report that apelin, a known regulator of pulmonary vascular 48 homeostasis, can potentiate the activity of CD39 both in vitro and in vivo. We conclude that 49 sustained attenuation of CD39 activity through ATP accumulation is tightly linked to vascular 50 dysfunction and remodelling in PAH and could represent a novel target for therapy. 51 52
7 pull down ECs for experimentation. Isolated cells were suspended to 200 μL RPMI 1640 and 172 used 10 μL/sample in enzyme assay. 173 174
Immunohistochemistry (IHC) and immunofluorecence (ICC) -staining 175
Formalin fixed and paraffin embedded lung tissues from three unrelated IPAH patients and 176 from three control patients, without previous history of pulmonary disease, were used for 177 staining. The primary antibodies used were anti-CD39 ( butanol, iso-amyl alcohol, diethylene glycol monoethylether, ammonia solution and milli-Q-210 aqua (9:6:18:9:15) (59). Previously applied standard mixture of 1 mM ATP, ADP, AMP, 211 adenosine, inosine, and hypoxanthine (Sigma) enabled visualization of all metabolites ranging 212 from ATP to hypoxanthine under UV-light. After separation radiolabelled bands containing 213 ATP-metabolites along with co-migrated non-labelled controls were scraped into 4 mL plastic 214 vials (PerkinElmer) with 0.5 mL of 0.2 M HCL and incubated for 1 h at room temperature 215 before adding 2.5 mL of scintillation mixture (Optiphase Hisafe 2, PerkinElmer, cat: 1200-216 436). After additional stay for, at least an hour, samples were quantified by scintillation β-217 counter (MicroBeta2 Plate counter, PerkinElmer). Because the exact cell number of ECs from 218 rat MCT series was unknown activities were normalized according to sample protein 219
concentration. 220 221
Basal level ATP homeostasis and adenosine production 222 ATP clearance was studied after physiological 2 μM ATP addition as previously described 223 (22) . Cells were plated into 24-well plates (50 000 cells per well) and cultured o/n in complete 224 media. The next day ECs were washed with basal salt solution (BSS, 130 mM NaCl, 5 mM 225 KCl, 1.5 mM CaCl2, 1 mM MgSO4, 25 mM HEPES, 5 mM glucose and 0.1% bovine serum 226 albumin; pH 7.4) and 1 mL of BSS, with or without ATP, was added into the wells. After 1h, 227 at 37°C in a conventional cell incubator, samples (800μL/well) were collected from the wells. 228
Samples were heat inactivated and centrifuged before ATP concentrations were determined 229 by using a method based on the luciferin/luciferase reaction according to the manufactures 230 instructions (ATPLite assay kit, Perkin Elmer, cat: 6016941). For adenosine production assay 231 human ECs were plated onto gelatin coated 12-well plates with complete media. Experiments 232 were started with confluent wells. Cells were washed once with BSS buffer. After washings 1 233 ml of 50 μM ATP in BSS buffer was added into the wells either with or without 1 μM of 234 human apelin-13 peptide. From the bathing medium we collected samples and measured Ado 235 concentrations as previously (22) . Shortly, adenosine was converted to H 2 O 2 with an enzyme 236 cascade comprising adenosine deaminase, xanthin oxidase, and purine nucleoside 237 phosphorylase (all from Sigma). The amount of H 2 O 2 was quantified with horseradish 238 peroxidase and amplex red reagent (Invitrogen, cat: A12222). In order to get only adenosine 239 signal, the signal from samples without adenosine deaminase was reduced from the samples 240 containing adenosine deaminase. 241
242

Western immunoblotting 243
For protein expression analysis confluent cell culture dishes were washed with 1xPBS, and 244 lysates were prepared by adding boiled cell lysis buffer (10 mM Tris HCL, 1% SDS, and 0.2 245 mM PMSF) containing protease and phosphatase inhibitors. Protein concentrations were 246 measured using Bradford dye-binding method (Protein assay, Bio-Rad). Samples were loaded 247 to Bolt 4-12% Bis-Tris gels with reducing agent and sample buffer recommended by 248 manufacturer (Invitrogen). Gels were blotted using iBlot dry blotting machinery (Invitrogen) 249 to nitrocellulose membranes. Membranes were blocked at least 1 h in (3% BSA, 0.1% TBS-250 Following primers were used: p2ry11 forward (5'-GAC TTC CTG TGG CCC ATA CT-3'), 274 reverse (5'-CAG CTG GAC AGA GAA GAC CA-3'); entpd1 forward (5'-GAG GAG CCT 275 CAG CAA CTA CC-3'), reverse (5'-TGA ATT TGC CCA GCA GAT AG-3'); β-actin 276 forward (5'-CAC TCT TCC AGC CTT CCT TC-3'), reverse (5'-GGA TGT CCA CGT CAC 277 density was calculated (cells/ml) under a microscope. Cell susceptibility to apoptosis was 291 determined by measuring caspase 3/7 activity (Caspase 3/7 assay, Promega, Nacka, Sweden, 292 cat: G8091). Cells were plated into 96-well white, clear bottom plates (8 000 cells per well) in 293 complete medium for o/n incubation in conventional cell incubator. Next day medium was 294 changed to serum free starvation medium for 6 hours with or without addition of ATP (2 μM) 295 or P2Y11 receptor agonist β-NAD (50 μM, Sigma). Caspase 3/7 levels were obtained by 296 adding 100 μl of caspase 3/7 luciferace reagent mix (Caspase-Glo ® Reagent) followed by 1 h 297 incubation before total luminescence was measured (Victor 2 1420 multilabel counter, Wallac, 298
Turku, Finland). 299 300
Cell viability assay 301
The viability of ECs was assessed with a XTT cell viability assay (Cayman chemical, Tallinn, 302 Estonia, cat: 10010200), which is based on extracellular reduction of XTT chemical by 303 NADPH. Cells were seeded into gelatin coated clear 96-well plates (4000 cells per well) with 304 complete medium for o/n incubation. Next day cells were washed once with 1XPBS before 305 addition of serum-free media for 6h. Serum-free medium was then changed to medium 306 containing 2% FCS either with or without addition of ATP (2 μM) or β-NAD (50 μM). After 307 24 hours of incubation in conventional cell incubator the XTT reagent was added and the 308 absorbance was measured at 450 nm. 309
310
SMC migration 311
SMC migration was analyzed with Transwell ® Permeable Supports, (Corning, Amsterdam, 312
The Netherlands) with 5 μm pore size, according to manufacturer's instructions. SMC cells 313
(10 000 cells per insert) were seeded into the inserts and let to attach in complete medium for 314 o/n. Next day medium was changed to basal culture medium with 1% serum following 315 addition of 2 μM ATP or 1μM apelin into the bottom well and then inserts were moved on top 316 of previously seeded ECs. The next day the inserts were washed and fixed with formalin and 317 stained with hematoxyllin and eosin. The number of cells migrated through the porous 318 membrane was calculated under light microscope. 319 320
Statistical Analysis 321
Values from multiple experiments are expressed, as means ± SEM and statistical significance 322 was tested using unpaired t-test or Mann-Whitney U-test. One-Way ANOVA with Bonferroni 323 correction was used when changes in parameter were studied at multiple time-points. Prism 324
GraphPad 6 (La Jolla, CA, USA) was used for statistical analyses. hydrolysing activity, which leads to increased ATP niche in the vascular wall. 341
342
Next we used ECs isolated from two other IPAH patients (IPAH 3 and IPAH 4) to evaluate 343 whether the observed attenuation of CD39 could be recapitulated and sustained in cell culture 344 conditions. Both of the IPAH patient ECs showed significant attenuation of CD39 mRNA 345 expression, as the expression was decreased by 97% and 69% (P=0.00058 and P=0.02) 346 (Figure 2A ). In addition, CD39 protein expression was decreased in human IPAH ECs 347 ( Figure 2B ). The down-regulation of CD39 enzyme expression was in line with the observed 348 57% decrease (P=0.014) in CD39 mediated specific ATP hydrolysing activity in IPAH 349 derived ECs, when compared to control ECs ( Figure 2C) . Furthermore, when we tested the 350 recovery to basal level after 2 μM ATP addition the control ECs hydrolysed 50% of the initial 351 model of pulmonary vascular disease, we utilized our magnetic-bead based in vivo profiling 354 strategy of CD39 activity. This magnetic-bead technology has been validated previously and 355
shown to efficiently capture changes in the endothelium up to ten days after MCT exposure 356 (33). In this strategy, isolated ECs were directly used in enzyme assays without cell culturing. 357
In line with our human studies, the ECs from MCT-injected animals showed significantly 358 decreased CD39 ATPase enzyme activity (45%, P=0.0001) five days after MCT injection and 359 remained at decreased level (26%, P=0.019) ten days after MCT injection, when compared to 360 control animals ( Figure 2D ). 361
362
CD39 deficient pulmonary ECs acquire an apoptosis resistant phenotype 363 364
To study the effects of CD39 suppression in ECs, we utilized siRNA techniques to efficiently 365 silence CD39 expression in healthy pulmonary ECs ( Figures 3A and 3B) . In ECs the loss-of 366 CD39 alone in control conditions and when stimulated with ATP both led to activation of 367 ERK1/2 ( Figure 3C ), suggesting that in these ECs the loss of CD39 leads to increased ATP 368 niche capable to activate the ERK1/2 pathway. These results are line with the previous reports 369 done with ATP (1). Furthermore, in these ECs the loss-of CD39 significantly increased the 370 survival response during serum starvation as seen by our cell-count experiments (20%; 371 P=0.0046, Figure 4A ). CD39-deficient ECs were also significantly more resistant to apoptosis 372 measured by caspase 3/7 activation (25%; P=0.019, Figure 4B ), and showed significantly 373 higher metabolic capacity in XTT-assays (30%; P=0.024, Figure 4C ) when compared to 374 control siRNA-treated ECs. In line with these observations, ATP treated ECs showed a 375 significant resistance to serum starvation based on caspase 3/7 activity (30%, P<0.0001, 376 Figure 4D ) and induced cell viability measured with XTT assay (100%, P=0.038, Figure 4E ) 377 when compared to control ECs. Interestingly, IPAH ECs stimulated with ATP showed total 378 resistance to the ATP-mediated survival and viability ( Figures 4F and 4G) , in contrast to the 379 observations from control ECs in similar conditions.
P2Y11 ATP receptor is vital for pulmonary EC ATP-mediated survival 382 383
As the ATP-mediated response is likely mediated through ATP binding receptors on the EC 384 surface we initiated a search for a candidate purinergic receptor. We evaluated the data from a 385 previously published microarray study on healthy human pulmonary ECs made deficient for 386 bone morphogenetic protein receptor 2 (BMPR2), a critical signaling molecule in the 387 pathogenesis of IPAH (2). The microarray analysis revealed that P2Y11 was the most 388 markedly dysregulated purinergic receptor upon acute loss-of BMPR2-mediated signaling. As 389 BMPR2 signaling is an important modulator of pulmonary EC survival (14) we hypothesized 390 that P2Y11, which solely recognizes only ATP as a substrate (13, 37)could be a significant 391 mediator of ATP responses and was selected as a candidate receptor for further studies. we used siRNAs to efficiently down-regulate P2Y11 expression in ECs ( Figures 6A and 6B) , 398
we observed a significant decrease in survival capacity of P2Y11-depleted ECs measured by 399 cell-count experiments (20%, P=0.0107) ( Figure 6C ) and significantly increased vulnerability 400 to serum starvation-induced apoptosis measured by caspase 3/7 activity assay (60%, 401 P=0.0059) ( Figure 6D ). Furthermore, P2Y11-deficient ECs showed decreased viability 402 compared to control siRNA-treated ECs (70%, P<0.0001, Figure 6E (Figures 7E and 7F) . 410 411 ATP rich microenvironment can induce pulmonary SMC migration and proliferation. 412
413
Next we analyzed if increased endothelial ATP niche, through suppression of CD39, could 414 influence surrounding SMCs by initiating a co-culture system. There was a significant 415 increase (20%) in SMC migration, through porous membrane, towards the CD39-deficient 416
ECs when compared to control ECs (P=0.021, Figure 8A ). Furthermore, with stimulation of 2 417 μM ATP we were able to increase the SMC migration by 30% (P=0.020, Figure 8B ). In line 418
with previously published studies (18)2 μM ATP stimulated 50% increase in SMC viability 419 (P=0.002, Figure 8C) . 420
421
CD39 ATPase activity is increased upon apelin treatment 422 423
Previous studies on hypoxia mouse model and MCT rat model have revealed that apelin is an 424 essential regulator of pulmonary endothelial homeostasis and has potential for PAH therapy 425 (2, 10)As the mechanisms of apelin-mediated therapeutic effects are unclear, we wanted to 426 evaluate whether apelin could affect purinergic homeostasis in pulmonary ECs. Interestingly, 427 overnight exposure to Apelin-13 peptide increased cell-bound CD39 ATPase activity in ECs 428 in a concentration dependent manner ( Figure 9A) , whereas, the peptide did not stimulate 429 soluble forms of ATPases (data not shown). The highest activation was observed with 1 μM 430 concentration, which increased the ATPase activity 300% (P<0.05). The 24h incubation with 431 1 μM apelin had no effect on CD39 expression on mRNA level (data not shown), suggesting 432 that apelin modulates the CD39 activity at post-translational level. To confirm the apelin-433 mediated activation of CD39 we measured the level of ATP breakdown product, adenosine, 434
and identified an increase in extracellular adenosine by 20% after an hour of exposure to 435 apelin (P=0.0289, Figure 9B ). The CD39-activating effect was identified also in experimentswith only 30 min exposure to apelin (60%, P=0.0002, Figure 9C) Figure 9E ). When ECs were co-cultured with pulmonary SMCs, 440 similarly done as in Figure 8A , the administration of 1 μM apelin for 6h caused a 40% 441 reduction in the migration of SMCs (P<0.0002) when compared to control conditions (Figure 442
activity between control and apelin treated healthy animals ( Figure 9G ). However, in the 447 MCT rat model of PAH, where CD39 activity is markedly reduced, we identified a significant 448 increase of ATPase activity upon apelin treatment (20%, P=0.0159) ( Figure 9G ). This result 449 confirms that, in addition to in vitro conditions, apelin can also modulate CD39 activity in 450 vivo, especially in conditions where CD39 activity is suppressed. 
456
Our study evaluating purinergic signalling in PAH pathogenesis reveals a significant 457 suppression of NTPDase1/CD39 ATPase expression and activity in diseased pulmonary 458 endothelium. This phenomenon was detected both in end-stage human IPAH patients and in a 459 rat model of PAH (Figures 1 and 2) . Based on our results, loss-of CD39 activity leads to 460 increased extracellular ATP, which can modulate the cell phenotype of both ECs and SMCs. 461
The loss-of CD39 could be associated with the phenotypic switch observed in pulmonary ECs 462 during PAH pathogenesis (36),as healthy ECs silenced for CD39 acquire an apoptosis 463 resistant and hyperproliferative phenotype similarly to ECs from IPAH patients (Figure 4) . 464
Interestingly, there were significant differences between small arteries within same IPAH 465 patient as the suppression of CD39 was most robust in the vessels with severe vascular 466 remodelling (Figure 1 ). This suggests that sustained CD39 expression could be protective 467 against vascular remodelling in PAH. This is supported by a study on angioplasty-induced 468 vascular injury, where over-expression of CD39 reduced the development of neointima (31). 469
However, CD39 enzymatic activity can also be regulated at post-translational level via 470 formation of multimers, which further increases the CD39 activity, or oxidative inactivation 471 (43, 46). We have previously shown similar constitutive CD39 suppression in chronically 472 hypoxic calf vasa vasorum ECs of which response to ATP and adenosine was dramatically 473
shifted (60). 474 475
The suppression of CD39 can lead to the accumulation of extracellular ATP and to decreased 476 extracellular adenosine levels. Short-term accumulation of ATP might be beneficial in 477 damaged vasculature as it can quickly improve vascular barrier function (26) and activate the 478 ERK 1/2 pathway in ECs and increase EC viability under stress ( Figure 3C ). In addition,extracellular ATP has shown to exert anti-inflammatory effects in an acute lung injury model 480 In addition to changes in adenosine production, suppression of CD39 can lead to 487 accumulation of ADP, which is an important stimulator of platelet activation at sites of injury 488 (55) (Figure 10 ). Furthermore, increased thrombosis has been recognized in patients with 489
severe PAH (11). In conclusion, our study reveals that sustained attenuation of endothelial 490 CD39 can propagate to apoptosis resistant ECs and increased ATP niche, which can further 491 stimulate SMC migration and proliferation (Figure 10) . 492
493
The role and function of P2Y11 in ECs are largely unknown. In our study P2Y11-deficient 494
ECs show abolished ATP-mediated survival and proliferation response suggesting that this 495 receptor is one of the major ATP binding receptors in pulmonary ECs (Figure 6 ). The effects 496 of P2Y11 on survival can be mediated either through calcium mobilization or through cAMP 497 pathways or both. The capability to activate both cAMP-mediated-and a phospholipase C-498 pathway is a unique feature of P2Y11 in comparison to other purine receptors (13). In contrast 499 to healthy ECs, IPAH patient derived ECs show complete resistance to ATP treatment-500 induced survival (Figure 4F-4G) . Endogenous ATP accumulation through sustained down-501 regulation of CD39 could mediate this inactivity to ATP signalling through saturation of P2 502 receptors, such as P2Y11. Based on our results it is possible that the turnover rate of P2Y11 503 receptor is slower in IPAH cells since or that due some other post translational regulation 504 mechanism there were no differences in mRNA expression level but a marked 50% difference 505 in the protein expression level (Figure 5) . Interestingly, P2Y11 siRNA-treated IPAH ECs20 became more sensitive to stress-induced apoptosis and loose their proliferation capacity 507 (Figure 6F-6G) . One of the reasons why the effect of P2Y11 mRNA silencing led to less 508 dramatic results as with control cells could be the altered post transcriptional regulation. One 509 of the major challenges in studying P2Y11 is that it is not, to our knowledge, expressed in 510 rodents. Identifying P2Y11 as an important P2 receptor in pulmonary microvascular ECs is 511 interesting, as it represents a significant difference between rodent and human pulmonary 512 endothelium, and could therefore account at least partly to the major differences between 513 rodent and human PAH. 514
515
Our observation that CD39-deficient ECs and ATP stimulate pulmonary SMC migration and 516 that extracellular ATP is a potent inducer of SMC proliferation (Figure 8 ) is in line with 517 previous reports (35, 53) and it represents an interesting mechanism how EC dysfunction can 518 promote SMC pathology and remodeling. These identified affects on SMCs can be mediated 519 through increased ATP and ADP concentration followed by P2 receptor activation, and also 520 through decreased adenosine levels. As adenosine is a potent inhibitor of SMC proliferation 521 and can promote SMC apoptosis, and it therefore represents an important modulator of intima 522
thickness (38). 523
Using human patient samples, in vitro strategies, and a rat model, we link for the first time, in 524 our knowledge, the suppression of CD39 to the pathogenesis of PAH. The suppression of 525 CD39 ATPase activity results in the accumulation of extracellular ATP and ADP and can 526 modulate the disease course in multiple levels (Figure 10 ). This motivated us to test novel 527 strategies to induce CD39 activity and therefore restore the balance in purinergic signaling. 528
Based on previous observations on apelin during PAH pathogenesis and it´s potential for 529 therapy in PAH both, in MCT and hypoxia mouse models (3, 19), we experimented whether 530 apelin levels could influence the extracellular purinergic homeostasis. These in vitro 531 experiments suggested that increased apelin levels lead to induced CD39 ATPase activity and 532 increased level of adenosine (Figure 9) . Furthermore, addition of apelin peptide was able to 533 inhibit EC-stimulated SMC migration and partly restore the decreased CD39 activity in our 534 rat model of PAH ( Figure 9F and 9G). Our in vivo study suggests that in normal physiological 535 conditions the activity of CD39 enzyme is at the level where the apelin administration was not 536 able to further increase the enzyme activity. This could suggest that the level of CD39 enzyme 537 activity is already at high level in normal pulmonary vasculature, for example through high 538 endogenous apelin levels, and cannot be further activated. Instead in diseased pulmonary 539 vasculature we identified a significant increase of CD39 enzyme activity after apelin 540 treatment ( Figure 9G ). This could reflect to biochemical properties of the suppressed CD39 541 levels or to lower endogenous levels of apelin, which has been reported in PAH (3). Since the 542 expression level of apelin receptor (APJ) in pulmonary ECs was below detection in our 543 experiments both in control and IPAH ECs (data not shown), as well as in previously reported 544 study (2), it is unclear how apelin delivers its functions in these cells. It would be intriguing 545 if some apelin peptides could modulate directly the CD39 activity. Altogether, our results 546 reveal that alterations in purinergic homeostasis can significantly contribute to pulmonary 547 vascular remodelling in PAH. We also show that these alterations can be closely linked to 548 other signalling pathways and molecules previously associated with PAH pathogenesis and 549 purinergic pathway represents an attractive target for future therapy in PAH. 
